Genmab A/S (NASDAQ:GMAB) is one of the top most undervalued biotech stocks to buy now. On August 7, William Blair analyst ...

Genmab AS (GMAB) reports a 19% revenue increase and a 56% rise in operating profit, showcasing strong financial performance ...

Genmab ( ($GMAB) ) just unveiled an update. On August 13, 2025, Genmab A/S announced updates to its Articles of Association, including ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

Genmab's Q3 earnings on November 6th are crucial, with expectations of $817M in revenue and $0.33 EPS. Read why I remain bullish on GMAB stock.

Genmab A/S (NASDAQ:GMAB) develops antibody therapeutics for the treatment of cancer and other diseases. H.C. Wainwright analyst Ram Selvaraju reiterated a “Buy” rating on the company’s ...

Genmab A/S (NASDAQ:GMAB) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 15, Genmab A/S (NASDAQ:GMAB) announced results from its EPCORE NHL-2 trial, Arm 10.

GMAB currently has a forward P/E ratio of 22.98, while TECH has a forward P/E of 34.77. We also note that GMAB has a PEG ratio of 0.93. This popular metric is similar to the widely-known P/E ratio ...

GMAB currently has a forward P/E ratio of 18.40, while INCY has a forward P/E of 42.67. We also note that GMAB has a PEG ratio of 0.71. This popular figure is similar to the widely-used P/E ratio ...